ArticleMedComm2024

Epidermal growth factor receptor‑targeted antibody nimotuzumab combined with chemoradiotherapy improves survival in patients with locally advanced head and neck squamous cell carcinoma: a propensity score matching real-world study.

Peng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.